GC-Rise Pharmaceutical To Launch Remifemin In China
This article was originally published in PharmAsia News
GC-Rise Pharmaceutical, a firm focusing on women's health, will launch Remifemin in the country soon. The drug, made from the extract of the medicinal plant black cohosh for treating menopausal symptoms, is produced by German company Schaper & Brümmer. Remifemin has been used worldwide for more than 50 years; its effectiveness and reliability have also been proven by strict trials in several Chinese authoritative clinical centers. Patients who are not candidates for hormone replacement therapy or who have concerns about the therapy's safety will have more choice after Remifemin enters the market. (Click here for more - Chinese Language)
You may also be interested in...
Purdue pleads guilty to three felony charges over marketing of OxyContin under settlement that requires Purdue to be dissolved and transformed into an entity that provides addiction and overdose medicines. Twenty-five state AGs oppose creation of a PBC, arguing Purdue should be sold to another company.
Abbott reported strong sales for diagnostics and devices in the third quarter and raised its full-year EPS guidance to $3.55 per share.
Vifor CEO Stefan Schulze tells Scrip that an expanded deal with Korsuva developer Cara Therapeutics means the US biotech will not have to invest in a commercial organization as the Swiss firm will mobilize its well-established sales force to launch the treatment for dialysis patients with CKD-associated pruritus.